About: Manipulation of the infectious bronchitis coronavirus genome for vaccine development and analysis of the accessory proteins

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Manipulation of the infectious bronchitis coronavirus genome for vaccine development and analysis of the accessory proteins Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Manipulation of the infectious bronchitis coronavirus genome for vaccine development and analysis of the accessory proteins
Creator	Britton, Paul Armesto, Maria Casais, Rosa Cavanagh, Dave Davies, Marc Hodgson, Teri Izadkhasti, Sousan Lin, Fengsheng Tarpey, Ian
Source	Elsevier; Medline; PMC
abstract	Abstract Infectious bronchitis coronavirus (IBV) is the cause of the single most economically costly infectious disease of domestic fowl in the UK—and probably so in many countries that have a developed poultry industry. A major reason for its continued dominance is its existence as many serotypes, determined by the surface spike protein (S), cross-protection being poor. Although controlled to some degree by live and inactivated vaccines, a new generation of IB vaccines is called for. Reverse genetic or ‘infectious clone’ systems, which allow the manipulation of the IBV genome, are key to this development. New vaccines would ideally be: genetically stable (i.e. maintain a stable attenuated phenotype); administered in ovo; and be flexible with respect to the source of the spike protein gene. Rational attenuation of IBV requires the identification of genes that are simultaneously not essential for replication and whose absence would reduce pathogenicity. Being able to modify a ‘core’ vaccine strain to make it applicable to a prevailing serotype requires a procedure for doing so, and the demonstration that ‘spike-swapping’ is sufficient to induce good immunity. We have demonstrated that four small IBV proteins, encoded by genes 3 and 5, are not essential for replication; failure to produce these proteins had little detrimental affect on the titre of virus produced. Our current molecularly cloned IBV, strain Beaudette, is non-pathogenic, so we do not know what effect the absence of these proteins would have on pathogenicity. That said, plaque size and composition of various gene 3/5 recombinant IBVs in cell culture, and reduced output and ciliostasis in tracheal organ cultures, shows that they are less aggressive than the wild-type Beaudette. Consequently these genes remain targets for rational attenuation. We have recently obtained evidence that one or more of the 15 proteins encoded by gene 1 are also determinants of pathogenicity. Hence gene 1 is also a target for rational attenuation. Replacing the S protein gene of Beaudette with that from the pathogenic M41 strain resulted in a recombinant virus that was still non-pathogenic but which did induce protection against challenge with M41. We have since made other ‘spike-swapped’ recombinants, including ones with chimaera S genes. Uniquely, our molecular clone of Beaudette is benign when administered to 18-day-old embryos, even at high doses, and induces immunity after this route of vaccination. Taken together, our results point to the creation of a new generation of IB vaccines, based on rational modification of the genome, as being a realisable objective.
has issue date	2007-07-26(xsd:dateTime)
bibo:doi	10.1016/j.vaccine.2007.02.046
bibo:pmid	17416443
has license	els-covid
sha1sum (hex)	ddfd2a01cc8bad81f00abe266c74159f5f2efd9b
schema:url	https://doi.org/10.1016/j.vaccine.2007.02.046
resource representing a document's title	Manipulation of the infectious bronchitis coronavirus genome for vaccine development and analysis of the accessory proteins
has PubMed Central identifier	PMC7115386
has PubMed identifier	17416443
schema:publication	Vaccine
resource representing a document's body	covid:ddfd2a01cc8bad81f00abe266c74159f5f2efd9b#body_text
is schema:about of	named entity 'simultaneously' named entity 'induce' named entity 'Infectious' named entity 'Being' named entity 'immunity' named entity 'serotypes' named entity 'genome' named entity 'SEROTYPE' named entity 'ATTENUATED' named entity 'ADMINISTERED' named entity 'DEGREE' named entity 'INACTIVATED VACCINES' named entity 'CORONAVIRUS' named entity 'CAUSE' named entity 'ALLOW' named entity 'A MAJOR' named entity 'REVERSE' named entity 'STABLE' named entity 'SUFFICIENT' named entity 'GOOD' named entity 'BEING' named entity 'PROBABLY' named entity 'CORONAVIRUS' named entity 'COUNTRIES' named entity 'SURFACE' named entity 'INFECTIOUS BRONCHITIS' named entity 'ITS' named entity 'NEW' named entity 'APPLICABLE' named entity 'PHENOTYPE' named entity 'RESPECT' named entity 'POOR' named entity '28S' named entity 'HAVE' named entity 'GENOME' named entity 'DETERMINED BY' named entity 'VACCINE STRAIN' named entity 'PROTEIN ' named entity 'IDENTIFICATION' named entity 'VACCINES' named entity 'FLEXIBLE' named entity 'ECONOMICALLY' named entity 'IN OVO' named entity 'INFECTIOUS BRONCHITIS' named entity 'DEMONSTRATION' named entity 'REPLICATION' named entity 'INFECTIOUS DISEASE' named entity 'GENES' named entity 'PROTECTION' named entity 'INDUCE' named entity 'PATHOGENICITY' named entity 'GENETIC' named entity 'SIMULTANEOUSLY' named entity '28I' named entity 'ACCESSORY' named entity 'TO MODIFY' named entity 'ABSENCE' named entity 'CONTINUED' named entity 'CROSS' named entity 'PROTEINS' named entity 'GENOME' named entity 'ANALYSIS' named entity 'GENERATION' named entity 'IBV' named entity 'SPIKE PROTEIN' named entity 'SINGLE' named entity 'LIVE' named entity 'MAKE' named entity 'PROTEIN GENE' named entity 'DOMESTIC FOWL' named entity 'SYSTEMS' named entity 'DOING' named entity 'IMMUNITY'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software